Achieve Life Sciences(ACHV)

SEATTLE, WABiotechnology1 H-1B visas (FY2023)

Focus: Achieve Life Sciences is a public-stage biotech company headquartered in Seattle focusing on small molecule therapeutics in oncology and smoking cessation. The company operates a lean, clinical-stage pipeline with multiple Phase 2 and Phase 3 programs.

Oncology Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Achieve Life Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Achieve Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OGX-427

Neoplasms

Phase 1

Clinical Trials (3)

NCT01844817Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer

Phase 2

Help build intelligence for Achieve Life Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active clinical pipeline with 6 Phase 3 trials underway, providing near-term value creation opportunities in oncology and smoking cessation
Public company status offers equity transparency and potential liquidity relative to private biotech
Diverse therapeutic focus spanning oncology (lung, breast, prostate) and nephrology/smoking cessation creates varied technical skill-building

Watch Out For

Severe cash burn ($29.8M net loss in FY2025, $42.4M in FY2024) with only $13M cash remaining signals potential financing crisis or dilution within 12–18 months
Zero active job openings and no recent hiring data suggest company is in cost-preservation mode, limiting career advancement and onboarding momentum
Pre-revenue status and absence of approved products mean no near-term revenue cushion; clinical trial failures could trigger restructuring

Generated by Claude from Achieve Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT02423590Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers

Phase 2

NCT00487786Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1

SN2310 Injectable Emulsion

Breast Neoplasms

Phase 1

Clinical Trials (1)

NCT00385177Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors

Phase 1

paclitaxel

Breast Cancer

Phase 1

Clinical Trials (5)

NCT00251095Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

Phase 3

NCT00034190Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma

Phase 2

NCT00034151Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

Phase 2

+2 more

OGX-427

Prostate Cancer

Phase 2

Clinical Trials (1)

NCT01681433OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Phase 2

OGX-427

Castration Resistant Prostate Cancer

Phase 2

Clinical Trials (1)

NCT01120470OGX-427 in Castration Resistant Prostate Cancer Patients

Phase 2

OGX-427

Bladder Cancer

Phase 2

Clinical Trials (1)

NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Phase 2

OGX-427

Non Squamous Non Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT01829113Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

Phase 2

cytisine

Smoking Cessation

Phase 2

Clinical Trials (5)

NCT03709823Trial of Cytisine in Adult Smokers

Phase 2

NCT03303911A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

Phase 1/2

NCT03848208A Single Dose-escalation Study of Cytisine in Adult Smokers

Phase 1

+2 more

paclitaxel

Non-Small Cell Lung Cancer

Phase 2

OGX-427 600 mg

Urologic Neoplasms

Phase 2

Clinical Trials (1)

NCT01454089A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Phase 2

apatorsen

Prostate Cancer

Phase 2

cytisinicline

Smoking Cessation

Phase 3

Clinical Trials (5)

NCT05206370A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

Phase 3

NCT07392125Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

Phase 3

NCT04576949A Study of Cytisinicline for Smoking Cessation in Adult Smokers

Phase 3

+2 more

paclitaxel

Breast Cancer

Phase 3

custirsen

Non-Small Cell Lung Cancer

Phase 3

Clinical Trials (5)

NCT01083615A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 3

NCT01578655Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Phase 3

NCT01630733A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Phase 3

+2 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 37 clinical trials

Top TAs: Oncology, Nephrology

H-1B (2023): 1 approval

Publications: 9 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

23 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Net Income

-$30M

Cash

$13M

Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(9)

Recent peer-reviewed publications with author affiliations at this company

Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco

2026

PMID:41885134

Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials.

Thorax

2026

PMID:40962497

Showing 5 of 9 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Achieve Life Sciences(ACHV)

About Achieve Life Sciences

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Achieve Life Sciences(10)

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship

Research Publications(9)